Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX and Lenvatinib Adjuvant Therapy for HCC Post-Transplant
NCT06409637Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06409637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409637.